SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-23-001157
Filing Date
2023-05-15
Accepted
2023-05-15 07:30:27
Documents
45
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bcli-20230331x10q.htm   iXBRL 10-Q 813470
2 EX-31.1 bcli-20230331xex31d1.htm EX-31.1 7726
3 EX-31.2 bcli-20230331xex31d2.htm EX-31.2 8336
4 EX-32.1 bcli-20230331xex32d1.htm EX-32.1 4952
5 EX-32.2 bcli-20230331xex32d2.htm EX-32.2 4980
  Complete submission text file 0001410578-23-001157.txt   2767401

Data Files

Seq Description Document Type Size
6 EX-101.SCH bcli-20230331.xsd EX-101.SCH 22906
7 EX-101.CAL bcli-20230331_cal.xml EX-101.CAL 26521
8 EX-101.DEF bcli-20230331_def.xml EX-101.DEF 57671
9 EX-101.LAB bcli-20230331_lab.xml EX-101.LAB 174086
10 EX-101.PRE bcli-20230331_pre.xml EX-101.PRE 133379
39 EXTRACTED XBRL INSTANCE DOCUMENT bcli-20230331x10q_htm.xml XML 294469
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

IRS No.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36641 | Film No.: 23918394
SIC: 2836 Biological Products, (No Diagnostic Substances)